Mylène Jansen

Long-term clinical success of KJD 51 3 Survival Survival after 9 years was 8 out of 17 patients (48%), as seen in Figure 1A. Survival analyses supported the differences found in survival percentage 9 years after treatment for sex (14% survival in women; 72% survival in men; p= 0.035; Figure 1B) and for initial increase in minimum JSW (0% survival in patients with <0.5mm increase; 73% survival in patients with >0.5mm increase; p= 0.002; Figure 1C). Figure 1 : (A) Survival curve of 20 patients with end-stage knee osteoarthritis treated with joint distraction. (B) Survival curve by sex, men (n=11) versus women (n=9). (C) Survival curve by increase in minimal joint space width (JSW) 1 year after treatment, less than 0.5 mm increase (n=7) versus more than 0.5 mm increase (n=13). Clinical outcome Survivors reported a statistically significant average 9-year increase in total WOMAC scores of 29.9 points (95%CI 16.9–42.9; p= 0.001; Figure 2A) compared to baseline. Surprisingly, also patients who underwent TKA in the years after KJD reported an average increase in total WOMAC scores of 20.5 points on last-reported scores compared to baseline (-1.8 to 42.8; p= 0.067; Figure 2A). Moreover, last-reported total WOMAC scores were not statistically significantly different between survivors and patients who received TKA after KJD (76.3 (60.3–92.4) and 65.8 (48.7–82.9); p= 0.317).